BDAZ,,,,,,,I know it would be an assumption,,but,,what do you think will be the main plot in these presentations?.....as in,,,,208 has an effect on cognitive decline in that it slows the decline or improves function etc!,,, It would be assumed that there must be a measurable beneficial effect from 208 in these test group of patients due to lessening of inflammation, plaque removal or is this just noise?  RVX probably would not push out negative or neutral news unless warranted!,,,,just thinking.

And am I correct in assuming that some or most of the sub group data from the BoM trial might be tabulated for public release well before the detailed top line results are issued?,,these presentations seem to indicate that.